{"schema_version":"secwatch.filing_event.v1","accession":"0001728117-22-000099","form_type":"8-K","ticker":"GOSS","cik":"0001728117","company_name":"Gossamer Bio, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.902761+00:00","generated_at":"2026-06-22T09:31:47.012263+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Gossamer Bio Q3 2022 net loss $59.4M; cash $304.4M; TORREY topline expected Nov/Dec","bullets":["Net loss $59.4M ($0.65/shr) vs $60.2M ($0.80/shr) in Q3 2021; cash $304.4M sufficient into Q2 2024.","R&D expenses $44.5M, G&A $11.5M for quarter ended Sep 30, 2022.","Phase 2 TORREY topline data for seralutinib expected in second half of Nov or first half of Dec 2022.","Enrollment ongoing in Phase 1b/2 STAR CNS study of GB5121 for relapsed/refractory CNS lymphomas.","Preclinical pipeline updates presented at multiple medical conferences; three internally developed programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001728117-22-000099","json":"https://secwatch.observer/filing/0001728117-22-000099.json","markdown":"https://secwatch.observer/filing/0001728117-22-000099.md","text":"https://secwatch.observer/filing/0001728117-22-000099.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728117/000172811722000099/0001728117-22-000099-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728117/000172811722000099/goss-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:31:47.012263+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"78cb78da7607bee539b140fc9b00aa22a4e2a873","claim":"Gossamer Bio, Inc. reported third quarter ended September 30, 2022 results: net income Net loss for the quarter ended September 30, 2022, was $59.4 million, or $0.65 per share, EPS $0.65 per share.","evidence_excerpt":"Gossamer Bio, Inc. (the \"Company\") issued a press release reporting its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1728117/000172811722000099/0001728117-22-000099-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Net income","value":"Net loss for the quarter ended September 30, 2022, was $59.4 million, or $0.65 per share"},{"label":"EPS","value":"$0.65 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}